PAINWeek 2018

Dr Zacharoff offered several tips to PAINWeek attendees to help improve their communication with patients.

A clinical pathway designed to reduce variations in opioid prescriptions for acute pain in children discharged after orthopedic surgery, was found to be effective in reducing prescriptions while maintaining analgesia.

DFN-11, a 3 mg subcutaneous (SC) sumatriptan autoinjector, may provide an alternative to SC sumatriptan 6 mg for individuals with episodic migraine, as it was found to have a lower incidence of side effects and injection site reactions.

Perioperative and emergency department use of non-steroidal anti-inflammatory drugs as part of a multimodal analgesia regimen may improve pain control in pediatric populations and avoid opioid-related adverse events.

Dr Prasad highlights the importance of interdisciplinary approaches to the management of chronic pain.

Naldemedine is a peripherally acting μ-opioid receptor antagonist approved for opioid-induced constipation in adults with chronic non-cancer related pain.

Investigator analyzed the number of scripts and days of therapy in patients with migraine to determine use and frequency of overuse.

Clinicians should get their patients tested for drugs before prescribing them opioid or benzodiazepine medications—and on a regular basis when patients are on those drugs—as drug-drug interactions may be associated with risks.

A topical lidocaine delivery system (ZTlido™) may be safe, effective, and well tolerated, and be bioequivalent to a lidocaine patch (Lidoderm®, 5%, 700 mg), with superior adhesion properties.

Lasmiditan was found to be more effective compared with placebo in eliminating pain and other symptoms associated with headache in individuals with migraine.